In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA (OBSV), with a price target of $44. The company’s shares closed yesterday at $10.94, close to its 52-week low of $9.73.
Selvaraju wrote:
“We consider nolasiban a highly differentiated agent, which should provide a clear pharmacoeconomic rationale based on its established profile of enhancement in IVF success rates. In 2015, according to the U.S. Prevention (CDC), only 26% of IVF cycles resulted in successful pregnancies. Thus, there is a clear unmet need in terms of improving the productivity of IVF treatment. As women in developed countries choose to have children later and later in life, the usage of IVF is positioned to only accelerate in the coming years. We also remind investors that historically double embryo transfer (DET) has been conducted in an attempt to increase IVF success rates, while SET is associated with higher birth weight, reduced incidence of prenatal and post-natal complications, and substantially reduced costs.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.3% and a 30.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on ObsEva SA is a Moderate Buy with an average price target of $41, representing a 274.8% upside. In a report issued on June 4, Wedbush also reiterated a Buy rating on the stock with a $38 price target.
See today’s analyst top recommended stocks >>
Based on ObsEva SA’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $20.13 million. In comparison, last year the company had a GAAP net loss of $19.81 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
